Call him if you have questions. He talks a mile a minute. Call him Afford. One thing I can tell you is that they seem to be very focused on the upcoming paper Dr. Bosch talked about and how regulators might react to it. Other than that, and what I've mentioned, he spoke too vaguely for me to remotely try to relay it.
AI4 Can I ask you something. IF the trail would have failed. Would the management then be so beneath all that is law and decency planning the next stage of DCVAXL being the combo trail with BMY/Keytruda in 2,5 weeks ?
I Mean that would not only be fooling shareholders, BMY, Keytruda and the FDA but also and more important the patients anticipating and hoping for treatment on Oct 1..?
Market Data 
Markets 
AI
